Table 3 Association between immune cell infiltration grade in tumors and clinicopathological parameters

Age (≤50 / >50 years)

36 (19.7) / 147 (80.3)

24 (22.6) / 82 (77.4)

rφ = −0.035

0.549

Invasive carcinoma (NST) / ILC / DCIS / Other invasive carcinomas

130 (71.0) / 22 (12.0) / 16 (8.7) / 15 (8.2)

77 (72.6) / 9 (8.5) / 17 (16.0) / 3 (2.8)

r_s = −0.019

0.743

DCIS status (Invasive DCIS − / Invasive DCIS +)

61 (36.7) / 105 (63.3)

31 (34.8) / 58 (65.2)

rφ = 0.019

0.761

DCIS grade (1–2 / 3)

62 (51.2) / 59 (48.8)

15 (20.0) / 60 (80.0)

rφ = 0.311

<0.01

Estrogen receptor status (ER − / ER +)

10 (6.1) / 154 (93.9)

33 (37.1) / 56 (62.9)

rφ = −0.394

<0.01

Progesterone receptor status (PR − / PR +)

20 (18.9) / 86 (81.1)

38 (51.4) / 36 (48.6)

rφ = −0.342

<0.01

HER2 status (HER2 − / HER2 +)

152 (92.1) / 13 (7.9)

62 (69.7) / 27 (30.3)

rφ = 0.294

<0.01

Tumor size (≤20 / 21–50 / >50 mm)

111 (66.9) / 47 (28.3) / 8 (4.8)

47 (52.8) / 40 (44.9) / 2 (2.2)

r_s = 0.122

0.052

Tumor grade (I / II / III)

72 (43.6) / 78 (47.3) / 15 (9.1)

13 (14.6) / 42 (47.2) / 34 (38.2)

r_s = 0.384

<0.01

Lymph node (− / +)

140 (76.5) / 43 (23.5)

63 (59.4) / 43 (40.6)

rφ = 0.180

<0.01

Involved lymph node (0 / 1–3 / >3)

140 (76.5) / 33 (18.0) / 10 (5.5)

63 (59.4) / 29 (27.4) / 14 (13.2)

r_s = 0.187

<0.01